Oxford Gene Technology Awarded £1.2m Genomics England Contract

13-Mar-2015 - United Kingdom

Oxford Gene Technology (OGT) announced it has been awarded a £1.2m phase two Small Business Research Initiative (SBRI) Healthcare contract. The contract is to develop next generation sequencing (NGS) analysis software, following the successful completion of phase one and an evaluation by Genomics England, UK Department of Health and Innovate UK.

Development of this technology will increase the accuracy and ease of interpreting whole genome genetic variant data by clinicians, supporting more precise treatment decisions. In addition to the analysis of NGS data, the software will integrate a full spectrum of genetic tests, including NGS, Sanger sequencing, microarray and fluorescence in situ hybridisation (FISH). The results of these tests will be put in context via the use of both public and private databases, providing the clinician with prioritised clinically-relevant results. These easy-to-understand reports will support faster diagnosis and better patient care.

James Clough, Executive Vice President Commercial, OGT said: “The award of this £1.2m contract underlines OGT’s position as a leading developer of cutting-edge products for molecular genetics. OGT has customers in over 60 countries worldwide and will use its extensive sales and marketing infrastructure to successfully commercialise the resulting product.”

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...